Nevertheless, studies in canine mammary cancer demonstrate that “speciation” of Cetuximab Fc is feasible, with the antibody preserving its affinity for EGFR and its anti-cancer effects in tumor cell lines, thus overcoming this issue (5, 41); therefore, in light of our protein alignment data and considering the high homology between canine, feline and human EGFR genes (5, 26), a similar future scenario is conceivable also in cat. The gene discussed is EGFR; the disease is cancer.